| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,272 |
10,980 |
$353K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
5,582 |
5,395 |
$215K |
| 62323 |
|
2,957 |
2,936 |
$167K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,734 |
6,519 |
$131K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,520 |
4,436 |
$98K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
364 |
346 |
$17K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,879 |
1,806 |
$10K |
| 99205 |
Prolong outpt/office vis |
63 |
62 |
$5K |
| 64483 |
|
60 |
53 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
39 |
39 |
$3K |
| J3490 |
Unclassified drugs |
667 |
629 |
$767.83 |
| 27096 |
|
25 |
24 |
$621.00 |
| 64484 |
|
30 |
26 |
$596.34 |
| 01936 |
|
12 |
12 |
$140.64 |
| 99152 |
|
15 |
14 |
$44.39 |
| J2704 |
Injection, propofol, 10 mg |
43 |
39 |
$4.03 |
| A4550 |
Surgical trays |
479 |
471 |
$3.04 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
1,444 |
1,384 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
2,901 |
2,728 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
567 |
555 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
1,979 |
1,885 |
$0.00 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
1,384 |
1,322 |
$0.00 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
1,868 |
1,781 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
3,406 |
3,252 |
$0.00 |
| G2201 |
Documentation of medical reason(s) for not providing brief counseling (e.g., limited life expectancy, other medical reasons) |
457 |
451 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
1,792 |
1,744 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
365 |
346 |
$0.00 |
| G9624 |
Patient not screened for unhealthy alcohol use using a systematic screening method or patient did not receive brief counseling if identified as an unhealthy alcohol user |
13 |
13 |
$0.00 |
| G9989 |
Documentation of medical reason(s) for not administering pneumococcal vaccine (e.g., adverse reaction to vaccine) |
12 |
12 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
27 |
27 |
$0.00 |
| G9991 |
Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period |
14 |
13 |
$0.00 |
| 1036F |
|
184 |
181 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
2,281 |
2,088 |
$0.00 |
| G2197 |
Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user |
459 |
451 |
$0.00 |
| A4455 |
Adhesive remover or solvent (for tape, cement or other adhesive), per ounce |
182 |
162 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
171 |
166 |
$0.00 |
| G9907 |
Documentation of medical reason(s) for not providing tobacco cessation intervention on the date of the encounter or within the previous 12 months (e.g., limited life expectancy, other medical reason) |
159 |
156 |
$0.00 |
| G9585 |
Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy |
13 |
13 |
$0.00 |